Sopharma (SFA) announced that the BoD adopted a decision to start a procedure for the merger of its subsidiary Veta pharma. SFA controls 99.98% stake in the subsidiary. Veta pharma reported sales of BGN 3.5m (-3.4% YoY) and net profit of BGN 0.2m (-27.4% YoY) in 2022. Recall that the main stakes in Veta pharma were acquired in 2016 and 2017 for a total of BGN 9.7m, while in 2020 the investment was partly impaired by BGN 2.9m.